High-Resolution Melting Analysis Using The Roche LightCycler Instrument For Rapid And Reliable Methylation Detection In Archival Tissue Samples
Main Category: Cancer / OncologyArticle Date: 12 Jul 2010 - 5:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Promoter hypermethylation is a frequent mechanism for the repression of gene transcription in cancer and is regarded as one of the hallmarks of cancer. Analysis of DNA methylation is a promising tool for early cancer detection, risk assessment, and response to therapy. In a recent study (1), quantitative high-resolution melting analysis (HRM) with the Roche (Pink Sheets: RHHBY) (SWX:RO) (SWX:ROG) LightCycler Instrument was used for promoter methylation for analysis of formalin-fixed paraffin-embedded (FFPE) tissues. Since FFPE tissue samples are the largest source of material from normal controls and diseased tissues, their use is of inestimable value for research. Methodical evaluations are of high importance for demonstrating robustness and sensitivity of the assay, thus facilitating its establishment as a research tool and possibly a future routine test.
The aim of the study was to establish and evaluate HRM assays for detection of promoter methylation on archival FFPE tissues from individuals with colorectal cancer. As proof of the principle, the researchers demonstrated the applicability of HRM for detection of promoter methylation using assays for O6-methylguanine-DNA methyltransferase (MGMT), adenomatous polyposis coli (APC), glutathione S-transferase P1 (GSTP1), and phosphatase and tension homolog deleted on chromosome 10 (PTEN) promoters in methylated DNA dilution matrix. In a second step, HRM assays for MGMT and APC were tested on DNA isolated from fresh and FFPE human cancer cell lines. These established MGMT and APC HRM assays were analyzed using archival FFPE colorectal tumor specimens. Methylated DNA levels as low as 1% were reproducibly detected in a background of unmethylated DNA. For certain applications, such as detection of rare events or risk stratification of individuals based on methylation status of specific markers, high sensitivity of the assay is important. This sensitive assay can be adapted and used to detect low amounts of methylated cells within a tumor, or even to detect low numbers of tumor cells in the background of non-tumor cells in lymph nodes and other organs.
The most popular approaches for DNA methylation detection rely on the treatment of genomic DNA with sodium bisulfite, which converts cytosine into uracil while leaving 5-methyl cytosine unmodified. This modification results in a sequence difference allowing for identification of methyl cytosines in a subsequent PCR amplification. The most precise methylation profiling can be achieved by bisulfite sequencing, which allows identification of single methyl cytosines. Several simpler PCR-based methods, which are especially important for small scale research labs, have also been developed. One of these newer and easier methods is high-resolution melting analysis (HRM), based on the "melting" properties of DNA in solution. The principle of this method is that bisulfite-treated DNA templates with different contents of methyl cytosine can be distinguished by melting analysis based on differences in melting temperatures. HRM is a relatively simple and cost-effective method, since it does not require expensive probes and reference gene assays for normalization. With HRM, all CpGs within the amplicon are analyzed, enabling the assay to distinguish heterogeneous from homogeneous methylation by the shape of the melting curve. This ability can be of importance, because methylation patterns at promoter CpG islands are typically not homogeneous.
(1) Roche Applied Science Cancer Research Application Note No. 3: M. Malic, M. Pichler, E. Heitzer, J. Strutz, N. Dandachi (2009) High quality assessment of DNA methylation in archival tissues from patients with colorectal cancer using quantitative high-resolution melting analysis
Source:
Roche
Visit our cancer / oncology section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/194424.php>
APA
http://www.medicalnewstoday.com/releases/194424.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




